Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme
Public ClinicalTrials.gov record NCT00083447. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID™ Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
TransMID treatment or best standard of care for patients with advanced glioblastoma multiforme Glioblastoma multiforme (GBM) is a type of brain tumour. GBM tumours are usually treated with surgery and radiotherapy. Unfortunately, this type of brain tumour may continue to grow or come back (recur) despite treatment. This trial will compare a new drug called TransMID with the best standard treatment that is currently available. TransMID is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. Cancer cells need iron in order to continue to grow. They need more iron than normal cells. Transferrin helps cells to take up available iron. So the cancer cells are attached to the transferrin in TransMID, and the diphtheria poison kills them. The aim of this treatment is to kill the cancer cells while not affecting the normal brain cells. This treatment for brain tumours may have fewer side effects than other treatments because it targets cancer cells. The best standard treatment will involve giving chemotherapy. You may have chemotherapy as part of the treatment when you are diagnosed. Or it may be kept in reserve to treat your brain tumour if it comes back or continues to grow. Your cancer specialist (consultant) will decide which chemotherapy drugs you should have.
Study identification
- NCT ID
- NCT00083447
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 323 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2004
- Primary completion
- Feb 28, 2006
- Completion
- May 31, 2007
- Last update posted
- Jan 6, 2009
2004 – 2007
United States locations
- U.S. sites
- 24
- U.S. states
- 19
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California-San Diego | La Jolla | California | 92037-0698 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| University of Colorado Health Sciences Center | Denver | Colorado | 80010 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Iowa Hospitals in Clinics | Cedar Rapids | Iowa | 52242 | — |
| University of Kentucky Medical Center | Lexington | Kentucky | 40536 | — |
| Johns Hopkins Medical Center | Baltimore | Maryland | 21287 | — |
| NINDS National Institutes of Health | Bethesda | Maryland | — | — |
| Fairview University Medical Center | Minneapolis | Minnesota | 55455 | — |
| Saint Louis University Hospital | St Louis | Missouri | 63110 | — |
| Cooper University Hospital | Camden | New Jersey | 08103 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| SUNY Upstate Medical University at Syracuse | Syracuse | New York | 13210 | — |
| New York Medical College | Valhalla | New York | 10595 | — |
| University of North Carolina - Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Legacy Emanuel Hospital and Technology Center | Portland | Oregon | 97227 | — |
| Temple University Hospital | Philadelphia | Pennsylvania | — | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Semmes-Murphey Neurologic Institute | Memphis | Tennessee | 38104 | — |
| University of Utah | Salt Lake City | Utah | 84132 | — |
| Medical College of Virginia | Richmond | Virginia | 23298-0631 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00083447, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2009 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00083447 live on ClinicalTrials.gov.